Can taking Palbociclib shrink tumors?

Palbociclib, in combination with any aromatase inhibitor, is the first hormone-based therapy for adults with ER+/HER2 metastatic breast cancer; in combination with fulvestrant, it is indicated for adult patients who have received hormone therapy for early-stage breast cancer or metastatic disease, regardless of their menopausal status.

The study showed that the combination of palbociclib and letrozole delayed disease progression for a median of 24.8 months. Patients' risk of disease progression was reduced by 42% and their tumor response was 55%, meaning more than half of the patients saw their tumors shrink in size. The combination of palbociclib and fulvestrant delayed disease progression for a median of 9.5 months, reducing patients' risk of disease progression by 54%. Tumor response was 24.6%, meaning 24.6% of patients saw their tumors shrink in size.

The original drug of palbociclib has been launched in China and has entered the scope of Class B medical insurance, but reimbursement is limited to patients who meet the indications. The price of each box may be more than more than 4,000 yuan. The price of palbociclib's original drug, 125mg*21 capsules, per box sold overseas may be more than RMB 10,000 (the price may fluctuate due to exchange rates). There are also generic palbociclib drugs produced in other countries. The price of 125mg*21 tablets produced by a Bangladeshi pharmaceutical factory may be around a few hundred yuan per box (the price may fluctuate due to the exchange rate). The price is cheaper. The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs.